Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET
Company Participants
Christine Chiou - Senior Vice President, Investor Relations
Samantha Du - Founder, Chairperson & Chief Executive Officer
Josh Smiley - President & Chief Operating Officer
Rafael Amado - President & Head-Global Oncology Research & Development
Harald Reinhart - President & Head-Global Development, Neuroscience, Autoimmune & Infectious Diseases
Yajing Chen - Chief Financial Officer
Jonathan Wang - Chief Business Officer
Conference Call Participants
Anupam Rama - JPMorgan
Louise Chen - Cantor
Michael Yee - Jefferies
Linhai Zhao - Goldman Sachs
Yigal Nochomovitz - Citigroup
Jonathan Chang - Leerink Partners
Jack Lin - Morgan Stanley
Operator
Hello, ladies and gentlemen, thank you for standing by and welcome to Zai Lab's First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer and instructions will follow at that time. As a reminder, today's call is being recorded.
It is now my pleasure to turn the floor over to Christine Chiou, Senior Vice President of Investor Relations. Please go ahead.
Christine Chiou
Thank you, operator. Good morning, good evening and welcome to Zai Lab's first quarter 2024 earnings call. Today's call will be led by Dr. Samantha Du, Zai Lab’s Founder, CEO and Chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr. Rafael Amado, President and Head of Global Oncology Research and Development, Dr. Harald Reinhart, President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, and Dr. Yajing Chen, Chief Financial Officer. Jonathan Wang, our Chief Business Officer will also be available to answer questions during the Q&A portion of the call.
As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectation. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings.
We will also refer to product revenue growth rate on a constant exchange rate basis, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on May 8, 2024 for additional information on this non-GAAP financial measure.
At this time, it is my pleasure to turn the call over to Dr. Samantha Du.
Samantha Du
Thank you, Christine, and good morning and good evening to all who are joining us today. I'm excited to be here to share with you the results from our first quarter. But before I do so, I want to start with a few opening comments. We started Zai Lab with a vision to build a truly innovative and integrated biopharma company, focused on bringing innovative medicines to address the unmet medical needs for patients in China and around the world. We have spent the past few years building our infrastructure, capabilities and pipeline to get us where we are today.